US merchandise and pharmacy retailer Fred’s has announced reaching a definitive agreement to sell certain assets of EntrustRX, a speciality pharmacy unit of Fred’s, to a subsidiary of retail pharmacy and healthcare firm CVS Health.

EntrustRx dispenses speciality pharmaceuticals across 50 states to treat complex conditions and diseases that typically require ongoing support for extended periods of time

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Its main therapy lines include hepatitis C, oncology, growth hormones, multiple sclerosis and rheumatology.

“One of Fred’s top priorities for 2018 has been to monetise non-core assets and we are pleased to have reached an agreement for the sale of EntrustRx.”

As part of the deal, the aggregate consideration to be paid by CVS is $40m, and an amount equal to the value of inventory of EntrustRX.

Fred’s interim CEO Joe Anto said: “One of Fred’s top priorities for 2018 has been to monetise non-core assets and we are pleased to have reached an agreement for the sale of EntrustRx.

“The cash proceeds will allow us to pay down a significant portion of our debt and also be used for general corporate purposes.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The transaction, scheduled to close by the end of this month, is subject to certain customary closing conditions.

Covington Associates and Bass Berry & Sims offered advisory consultation to Fred’s on this transaction.

Fred’s acquired EntrustRx, along with its parent company Reeves-Sain Drug Store, for $66m in April 2015.

Headquartered in Coldwater, Mississippi, Fred’s currently operates approximately 600 general merchandise and pharmacy stores, including 12 franchised locations and three speciality pharmacy-only locations.

The drug store chain currently offers nationally recognised brands, own-label products and a range of value-priced selections.